ArticleiScience2025
Reactive oxygen species-responsive hydrogel loaded with melatonin as a minimally invasive treatment for myocardial I/R injury.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Melatonin-Hydrogel Delivery Systems for Effective Treatments of Periodontitis: Translational Perspectives from Material Designs to Clinical Applications.Gels (Basel, Switzerland) · 2026Review
- Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy.Materials today. Bio · 2026Review
- Research advances in intelligent microenvironment-responsive hydrogels for myocardial infarction therapy.APL bioengineering · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) poses a severe threat to human life, and timely reperfusion of ischemic myocardium stands as the most effective treatment approach. However, myocardial ischemia-reperfusion (I/R) could lead to the excessive generation of reactive oxygen species (ROS), worsening myocardial injury. In this investigation, an ROS-responsive injectable hydrogel encapsulating melatonin (MLT) was synthesized. This hydrogel could provide a controlled release of MLT, markedly enhancing its antioxidant, anti-inflammatory, anti-apoptotic, and autophagy-modulating effects, thereby significantly mitigating myocardial ischemia-reperfusion injury (MIRI). Moreover, this study proposes an injection method of ultrasound delivery, which offers significant advantages to MI patients without the necessity of thoracotomy. In conclusion, This ROS-responsive hydrogel loaded with MLT established the basis for minimally invasive treatment of myocardial I/R injury, which has considerable potential for the treatment of MIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.